Article
Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 15 Apr 2017
Collier Dami, Iwuji Collins, Derache Anne, de Oliveira Tulio, Okesola Nonhlanhla, Calmy Alexandra, Dabis Francois, Pillay Deenan, Gupta Ravindra K
Abstract excerpt
Background: Second-line antiretroviral therapy (ART) based on ritonavir-boosted protease inhibitors (bPIs) represents the only available option after first-line failure for the majority of individuals living with human immunodeficiency virus (HIV) worldwide. Maximizing their effectiveness is imperative. Methods: This cohort study was nested within the French National Agency for AIDS and Viral Hepatitis Research...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.